All results

33 results for randomized double blind placebo controlled study assess efficacy safety and

• ATYR

  This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…

  Ages

  18 Years - 75 Years

  Sexes

  All

• EMBARK

  The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The…

  Ages

  4 Years - 7 Years

  Sexes

  Male

• Adaptive COVID-19 Treatment Trial (ACTT)

  This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized…

  Ages

  18 Years - 99 Years

  Sexes

  All

• PROTECT Extension Study

  The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in…

  Ages

  9 Years - 19 Years

  Sexes

  All

• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

  This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…

  Ages

  18 Years - N/A

  Sexes

  All

• MOM-M281-006

  The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA). The study consists…

  Ages

  18 Years - N/A

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• United therapeutics 301

  Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of…

  Ages

  18 Years - N/A

  Sexes

  All

• GALACTIC-1

  This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and…

  Ages

  40 Years - N/A

  Sexes

  All

• REPLENISH

  The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52…

  Ages

  50 Years - N/A

  Sexes

  All